Document is current
Any future updates will be listed below
-
Authors
Sierra-Davidson, Kailan
Dedeilia, Aikaterini
Lawless, Aleigha
Sharova, Tanya
Kaufman, Howard L.
Boland, Genevieve M.
Cohen, Sonia
-
Funding
Funding for this research was provided by:
Harvard Catalyst/The Harvard Clinical and Translational Science Center (National Institutes of Health Award KL2 TR002542)
- License Information
-
More Information
Article History
Received: 5 July 2024
Accepted: 26 September 2024
First Online: 18 October 2024
Disclosure
: Howard L. Kaufman is an employee of Ankyra Therapeutics, and serves on advisory boards for Castle Biosciences, Marengo Therapeutics, Jenga Biosciences, Virogin, and Tatum Biosciences. Genevieve M. Boland has sponsored research agreements, through her institution, with Olink Proteomics, Teiko Bio, InterVenn Biosciences, and Palleon Pharmaceuticals; has served on advisory boards for Iovance, Merck, Nektar Therapeutics, Novartis, and Ankyra Therapeutics; consults for Merck, InterVenn Biosciences, Iovance, and Ankyra Therapeutics; and holds equity in Ankyra Therapeutics. She is supported by the Adelson Medical Research Foundation, the Emma and Bill Roberts MGH Research Scholar Award, the Melanoma Research Alliance, and the Department of Defense. Sonia Cohen is supported by the Harvard KL2/Catalyst Medical Research Investigator Training Award, the Adelson Medical Research Foundation, and the National Institutes of Health. Kailan Sierra-Davidson, Aikaterini Dedeilia, Aleigha Lawless, and Tanya Sharova have no conflicts of interest to declare that may be relevant to the contents of this study.
